Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
South Africa
0
Weekly News Recap #Phispers
1. Bms 907351
2. Bms-907351
3. Bms907351
4. Cabozantinib
5. Cometriq
6. Xl 184
7. Xl-184
8. Xl184 Cpd
1. 1140909-48-3
2. Cabozantinib Malate
3. Cabozantinib (s)-malate
4. Cabometyx
5. Cabozantinib Malate (xl184)
6. Xl184
7. Cabozantinib (s-malate)
8. Cometriq
9. Cabozantinib S-malate [usan]
10. Dr7st46x58
11. Bms907351
12. Chebi:72319
13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
14. Cabometyx (tn)
15. Cometriq (tn)
16. Cabozantinib Malate (jan)
17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid
18. Cabozantinib S-malate (usan)
19. Cabozantinib Malate [jan]
20. Unii-dr7st46x58
21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
23. Xl184 Malate
24. Cabozantinib L-malate
25. Bms907351 Malate
26. Xl184(cabozantinib Malate)
27. Mls006010951
28. Chembl2103868
29. Dtxsid60915949
30. Ex-a2819
31. Mfcd20923480
32. S4001
33. 1140909-48-3 (malate)
34. Akos025401945
35. Cabozantinib S-malate [who-dd]
36. Ccg-270301
37. Cs-0201
38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor
39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
40. Ac-27471
41. As-75255
42. Hy-12044
43. Smr004702755
44. Cabozantinib S-malate [orange Book]
45. Sw218093-2
46. D10095
47. Q27139901
48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)
52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt
53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)
54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate
Molecular Weight | 635.6 g/mol |
---|---|
Molecular Formula | C32H30FN3O10 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 11 |
Exact Mass | 635.19152232 g/mol |
Monoisotopic Mass | 635.19152232 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 46 |
Formal Charge | 0 |
Complexity | 924 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
* Renal Cell Carcinoma (RCC):
Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):
- in treatment-nave adults with intermediate or poor risk,
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
* Hepatocellular Carcinoma (HCC):
Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
L01EX07
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 20 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 40 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 60 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form :
Dosage Strength :
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form :
Dosage Strength :
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Cometriq
Dosage Form : Capsule, hard
Dosage Strength : 20 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablets
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablets
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablets
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Cometriq
Dosage Form : HARD CAPSULES
Dosage Strength : 20 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cabozantinib S-Malate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib S-Malate, including repackagers and relabelers. The FDA regulates Cabozantinib S-Malate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib S-Malate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabozantinib S-Malate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabozantinib S-Malate supplier is an individual or a company that provides Cabozantinib S-Malate active pharmaceutical ingredient (API) or Cabozantinib S-Malate finished formulations upon request. The Cabozantinib S-Malate suppliers may include Cabozantinib S-Malate API manufacturers, exporters, distributors and traders.
click here to find a list of Cabozantinib S-Malate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cabozantinib S-Malate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib S-Malate active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib S-Malate DMFs exist exist since differing nations have different regulations, such as Cabozantinib S-Malate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cabozantinib S-Malate DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib S-Malate USDMF includes data on Cabozantinib S-Malate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib S-Malate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cabozantinib S-Malate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cabozantinib S-Malate Drug Master File in Korea (Cabozantinib S-Malate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib S-Malate. The MFDS reviews the Cabozantinib S-Malate KDMF as part of the drug registration process and uses the information provided in the Cabozantinib S-Malate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cabozantinib S-Malate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib S-Malate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cabozantinib S-Malate suppliers with KDMF on PharmaCompass.
A Cabozantinib S-Malate written confirmation (Cabozantinib S-Malate WC) is an official document issued by a regulatory agency to a Cabozantinib S-Malate manufacturer, verifying that the manufacturing facility of a Cabozantinib S-Malate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib S-Malate APIs or Cabozantinib S-Malate finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib S-Malate WC (written confirmation) as part of the regulatory process.
click here to find a list of Cabozantinib S-Malate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib S-Malate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib S-Malate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabozantinib S-Malate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib S-Malate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib S-Malate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabozantinib S-Malate suppliers with NDC on PharmaCompass.
Cabozantinib S-Malate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cabozantinib S-Malate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib S-Malate GMP manufacturer or Cabozantinib S-Malate GMP API supplier for your needs.
A Cabozantinib S-Malate CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib S-Malate's compliance with Cabozantinib S-Malate specifications and serves as a tool for batch-level quality control.
Cabozantinib S-Malate CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib S-Malate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cabozantinib S-Malate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib S-Malate EP), Cabozantinib S-Malate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib S-Malate USP).
LOOKING FOR A SUPPLIER?